Natasha B. Leighl
娜塔莎·莱尔
MD, MMSc
Medical Oncologist; Professor of Medicine; Program Director, Thoracic Cancers肿瘤内科医生；医学教授；胸部肿瘤项目主任
👥Biography 个人简介
Natasha B. Leighl, MD, MMSc, is a Medical Oncologist and Professor of Medicine at Princess Margaret Cancer Centre in Toronto, where she directs the Thoracic Cancers Research Program. She is one of the foremost clinical investigators in EGFR-mutant NSCLC and was a key investigator in the MARIPOSA and MARIPOSA2 trials evaluating amivantamab plus lazertinib in EGFR-mutant NSCLC. MARIPOSA2 established amivantamab plus lazertinib (with or without chemotherapy) as an active regimen for patients with EGFR-mutant NSCLC after progression on osimertinib, a critical unmet need given that virtually all patients on osimertinib eventually develop resistance. Amivantamab, a bispecific antibody targeting EGFR and MET, combined with lazertinib (a third-generation EGFR TKI) provides dual inhibitory pressure on the EGFR signaling axis. MARIPOSA further evaluated this combination as first-line therapy in EGFR-mutant NSCLC, demonstrating superior PFS compared to osimertinib monotherapy. Leighl has additionally led studies on patient-reported outcomes in lung cancer trials, equity in access to molecular testing, and the integration of circulating tumor DNA in EGFR-mutant NSCLC management. Her work bridges rigorous clinical trial execution with advocacy for equitable implementation of precision oncology in diverse healthcare settings.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
MARIPOSA2: Amivantamab plus Lazertinib after Osimertinib
Co-investigator of MARIPOSA2 demonstrating clinical activity of amivantamab plus lazertinib combination regimens in EGFR-mutant NSCLC after osimertinib progression, addressing the critical unmet need of post-third-generation TKI management and validating EGFR-MET bispecific antibody combinations.
MARIPOSA: First-Line Amivantamab plus Lazertinib
Participated in MARIPOSA evaluating amivantamab plus lazertinib as first-line therapy for EGFR-mutant NSCLC, demonstrating superior PFS compared to osimertinib monotherapy and establishing a new first-line doublet option for this population.
Equity in Molecular Testing and Biomarker-Driven Care
Led national and international studies on disparities in access to comprehensive molecular profiling and targeted therapies in NSCLC across socioeconomic and geographic groups, identifying barriers and designing interventions to promote equitable precision oncology delivery.
Representative Works 代表性著作
Amivantamab plus Lazertinib in EGFR-Mutant Advanced NSCLC after Osimertinib (MARIPOSA2)
Annals of Oncology (2023)
Phase III trial showing that amivantamab plus chemotherapy and amivantamab plus lazertinib plus chemotherapy achieve significant PFS benefit over chemotherapy alone in EGFR-mutant NSCLC post-osimertinib, establishing combination regimens as post-osimertinib standards.
Amivantamab plus Lazertinib versus Osimertinib as First-Line Treatment in EGFR-Mutant Advanced NSCLC (MARIPOSA)
New England Journal of Medicine (2024)
Phase III trial demonstrating superior PFS with amivantamab plus lazertinib versus osimertinib monotherapy as first-line therapy for EGFR-mutant advanced NSCLC, establishing a new first-line doublet standard for this population.
Molecular Testing for Selection of Patients with Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Journal of Thoracic Oncology (2018)
Consensus guideline establishing evidence-based standards for molecular testing in lung cancer, defining the required markers and appropriate testing platforms to guide selection of patients for EGFR, ALK, ROS1, and other targeted therapies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 娜塔莎·莱尔 的研究动态
Follow Natasha B. Leighl's research updates
留下邮箱，当我们发布与 Natasha B. Leighl（Princess Margaret Cancer Centre, University Health Network, University of Toronto）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment